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Abstract
superactive leptin antagonists (D23l/l39a/D40a/F41a), mutants of mouse, human, 
rat or ovine leptons, were developed in our laboratory, expressed in E. coli, refolded 
and purified to homogeneity as monomeric proteins.   pegylation of  leptin antagonists 
resulted in a potent and effective long-acting reagents suitable for in vivo studies.  In the 
present review we summarize the possible use of leptin antagonists as (i) research re-
agents in the study of bone development, autoimmune diseases, metabolic syndrome 
and type 2 diabetes mellitus (T2Dm) with particular emphasis on creation of a novel, 
fast and reversible model of metabolic syndrome and T2Dm in mice, and (ii) possible 
leptin blockers in various human pathologies such as uremic cachexia, anti-inflamma-
tory and anti-autoimmune diseases, and cancer. In conclusion, the recognition and 
mutagenesis of D23l of previously developed leptin antagonists (l39a/D40a/F41a) 
enabled construction of novel compounds that induce potent and reversible central 
and peripheral leptin deficiency. 
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Development of potent leptin 
antagonists
Though leptin and leptin receptor 
(LEPR) were cloned almost 20 years 
ago (1,2) and leptin’s 3D structure 
has been resolved (3), the mechanism 
of leptin:LEPR interaction and ac-
tivation has not yet been elucidated. 
Nevertheless, several putative models 
have been proposed (4). The extra-
cellular domain (ECD) of LEPR, as 
depicted in Figure 1, consists of sev-
eral subdomains termed (from the N-
terminus): cytokine homology region 
1 (CHR 1), followed by an immuno-
globulin-like domain (IGD), then by 
another CHR 2 and finally by two 
consecutive F3 domains. Fong and 
co-workers (5) localized the leptin-
binding domain to the membrane-
proximal CHR 2 (~ 200 amino acids) 
in the LEPR-ECD. This domain from 
human (6) and chicken LEPRs (7) 
was subcloned in our laboratory and 
expressed as a recombinant protein 
which showed a 1:1 molar interaction 
with leptin. Over 10 years  ago, Tav-
ernier and his group (8) revealed that 
leptin binding to its receptor resem-
bles the interaction between interleu-
kin 6 (IL-6) and IL-6 receptor (9-11), 
and they formulated the existence of 
Adipobiology 4, 2012
Superactive leptin antagonists6 Review
the putative leptin site III as a major site responsible for the 
formation of active 2:2 or 2:4 leptin:LEPR complex. The IGD 
located between the distal and proximal CK-F3 domains was 
clearly documented to be essential for productive dimerization 
(or even tetramerization) of the LEPR, as its removal attenu-
ated activation, but not binding, of the ligand (8). Schematic 
illustration of 2:2 leptin:LEPR complex showing interaction 
of two leptin molecules, each with the CHR 1 of one receptor 
(through binding site 1/2) and with the IGD of the second re-
ceptor (through binding site 3) is presented in Figure 1. This 
model was further substantiated by the extensive mutagenesis 
of mouse and human leptins which led to the identification of 
Ser 120 and Thr 121, located in the N-terminal part of helix D, 
as contributors to site III (12). Mutation of these amino acids to 
Ala led to the formation of leptin antagonist. In addition to the 
N-terminal part of helix D, we have employed a sensitive bidi-
mensional Hydrophobic Cluster Analysis (13) and by compari-
son to known structures of IL-6-receptor complexes (viral (v) 
IL-6/gp130) (9) and IL-6/IL-6Rα/gp130 complex (10) in which 
site III was first identified, we have identified amino acids L39/
D40/F41/I42 in the A-B loop in leptin to be responsible for 
interaction with the receptor that leads to functional dimeri-
zation or tetramerization required for receptor activation.  To 
verify this hypothesis and to test its generality, we prepared and 
purified to homogeneity several ovine and human recombinant 
leptin Ala muteins in the A-B loop (L39A/D40A, L39A/D40A/
F41A or L39A/D40A/F41A/I41A) and documented their activ-
ity as potent competitive LEPR antagonists (14). To verify the 
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Figure 1. schematic illustration of the interaction of two leptin molecules with the extracellular domains of two leptin receptors. 
The first leptin molecule (designed as a brown-solid line oval) interacts through its 1/2 binding site with the cytokine homology 
domain 2 (chR 2) of the left receptor and subsequently through its binding site 3 with the immunoglobulin-like domain 2’ (IgD’) 
of the second receptor. In parallel the second leptin molecule (designed as a green-pointed line oval) interacts through its 1/2 
binding site with the chR 2’ of the right receptor and subsequently through its binding site 3 with the (IgD) of the left receptor. 
There is no known interaction between the two leptins. mutations l39a/D40a/F41a abolish the interaction of leptins with the 
IgDs, preventing receptor activation but not the binding to chR2 domains and just acts as antagonist.  mutation D23l increases 
the affinity of leptin (or leptin antagonist) toward chR-2. 
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preservation and importance of this sequence for activation of 
LEPRs, we also prepared the corresponding muteins of mouse 
and rat leptin and documented their antagonistic activity (15). 
In a subsequent work, we increased the half-life of the leptin 
antagonist by pegylation, resulting in significant extension of 
its bioavailability while retaining antagonistic activity (16). In 
mice, administration of the pegylated antagonist produced 
rapid and dramatic weight gain, due to enhanced appetite and 
increased food consumption. The resulting fat was confined to 
the mesenteric region with no accumulation in the liver. Re-
markably, weight changes were reversible upon cessation of 
leptin-antagonist treatment. The mechanism of severe central 
leptin deficiency was found to involve inhibition of leptin trans-
port across the blood-brain barrier, as well as accumulation of 
pegylated antagonist within the central nervous system and di-
rect inhibition of LEPRs in the hypothalamic region. 
In view of the potential pharmaceutical uses of leptin antago-
nists, the general question of how the biopotency of recombi-
nant proteins can be enhanced in vivo needs to be explored. One 
possible approach is to increase the antagonist’s affinity for the 
receptor by increasing kon, or mainly by decreasing koff, and thus 
prolonging receptor occupation. Theoretical thermodynamic 
considerations show that if antagonists and agonists exhibit the 
same affinity, at a 100-fold molar excess of antagonist, 99% of all 
occupied receptors will be occupied by antagonists. A 100-fold 
increase in antagonist affinity will lead to similar results at an ap-
proximate 1:1 molar antagonist:agonist ratio. Pegylation of such 
muteins combines both approaches, resulting in a potent and 
effective long-acting competitive antagonist in vivo. To explore 
this approach, we employed random mutagenesis of mouse 
leptin followed by selection of high-affinity mutants by yeast-
surface display, and discovered that replacing residue D23 with 
a non-negatively charged amino acid leads to dramatically en-
hanced affinity of leptin for LEPR. Rational mutagenesis of D23 
revealed the D23L substitution to be the most effective. Cou-
pling the D23 mutation with Ala mutagenesis of three amino 
acids (L39A/D40A/F41A) previously reported to convert leptin 
into antagonist (14, 15) resulted in potent antagonistic activity 
(17). Those novel superactive mouse and human leptin antago-
nists (D23L/L39A/D40A/F41A) termed, respectively, SMLA 
and SHLA, exhibited over 60-fold increased binding to LEPR 
and 14-fold higher antagonistic activity in vitro relative to the 
L39A/D40A/F41A mutants. To prolong and enhance the in vivo 
activity, SMLA and SHLA were monopegylated mainly at the N 
terminus. Administration of the pegylated SMLA to mice result-
ed in a remarkably rapid, significant and reversible 27-fold more 
potent increase in body weight as compared to pegylated MLA 
(Table 1). To test whether the D23L mutations confer increased 
affinity in other leptin species, we have recently prepared D23L/
L39A/D40A/F41A muteins of ovine (18) and rat leptins (G. Sol-
omon and A. Gertler, unpublished results) and found that they 
also act as potent leptin antagonists.
table 1.  Effect of pEg-mla and pEg-smla on weight gain in male mice determined one and two weeks after initiation of the 
injections. Each material was injected daily at 20, 6.7, 2.2 and 0.72 mg/kg, n = 8. The results are presented as % of body mass 
change (mean ± sEm). The initial body weight was 20 to 22 g. 
Material injected mg/kg/day One week Two weeks
control – 0.5 ± 0.1   0.9 ± 0.6
pEg-mla 0.73 7.8 ± 0.8a 11.3 ± 1.3a
       “ 2.2 10.1 ± 0.9b 14.7 ± 1.5ab 
       “ 6.7 12.0 ± 1.3b 16.6 ± 1.8b
       “ 20.0 18.7 ± 2.0c 22.8 ± 1.5c 
pEg-smla 0.73 12.7 ± 2.1b 22.0 ± 2.1c
       “ 2.2 19.6 ± 1.7c 30.2 ± 2.3d 
       “ 6.7 27.3 ± 2.1d 42.3 ± 1.8e 
       “ 20.0 29.0 ± 2.6d 44.7 ± 3.4e
all groups in the same column not designated with the same letter are significantly different  (p < 0.05).
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leptin antagonist-induced rapid and reversible mouse 
model of metabolic syndrome and type 2 diabetes 
mellitus   
Obesity and its major consequence, type 2 diabetes mellitus 
(T2DM), has become an epidemic, globally.  T2DM accounts for 
95% of the diabetes worldwide. One limitation to the develop-
ment of new diabetes treatments has been a lack of effective ani-
mal models to use in research. There are no rodent models that 
recapitulate the pancreatic β-cell lesions of humans with T2DM. 
Moreover, animal models of obesity require either overfeeding, 
which is expensive and takes weeks to months to establish, or 
specific genetic mutations that cause lifelong metabolic dysfunc-
tion. Thus the ability to rapidly induce obesity in healthy rat and 
mouse strains would constitute a major advance in diabetes and 
obesity research leading to the development of novel therapies. 
As shown above PEG-SMLA has strong orexigenic properties, 
and when given to mice every 24 to 48 h leads to remarkable 
weight gain. So far, over 15 experiments have been performed 
over the course of 2 to 12 weeks to test the effects of PEG-SMLA 
on weight gain in mice, achieving a uniform 25 to 45% weight 
gain in 14 to 21 days. Some representative data from these stud-
ies including long term experiment in female mice started at the 
age of 4 weeks and ended at the age of 4 months are presented 
in Table 2. The results clearly show that weight gain is accom-
panied by elevated glucose, cholesterol and triglyceride levels, 
and an even more dramatic increase in insulin levels and insulin 
resistance (HOMA-IR). Interestingly, no hepatic damage was 
observed, even after 12 weeks of treatment, although morpho-
logically the livers of PEG-SMLA-treated animals seem fatty. 
PEG-SMLA treatment did not affect other blood parameters 
such as albumin, globulin, creatinine, urea, calcium, potassium, 
phosphorus or bilirubin (not shown).  An additional experiment 
was carried out to test the effects of PEG-SMLA, and showed 
abnormal glucose tolerance (by oral glucose tolerance test) af-
ter 3 weeks of treatment. This change, along with others such as 
weight gain, increased fat content, hyperinsulinemia and hyper-
triglyceridemia, were fully reversible with cessation of PEG-SM-
LA injections, disappearing within 10 to 14 days (not shown).
Determining insulin and glucose levels and HOMA scores 
can indicate whether mice are normal (euglycemic with normal 
insulin levels), insulin-resistant, or have developed T2DM ac-
cording to the following criteria:
Normal: Glucose and insulin are less than 2.5 SD above con-
trol average 
Insulin-resistant (metabolic syndrome): Insulin more than 
2.5 SD above control average but glucose less than 2.5 SD above 
table 2. Weight gain and selected biochemical and hormonal parameters in 8-week-old male and 4-week-old female mice after 
long-term 4 or 12 weeks Ip administration of pEg-smla at 12 (male) or 5 (female) mg/kg daily.
Males1 Females2
after 4 weeks after 4 week after 12 weeks
control PEG-SMLA Control PEG-SMLA Control PEG-SMLA
Weight gain (%) 15 ± 0.3 65 ±1.2**  20 ± 1 69 ± 7***   39 ± 4 124 ± 6***
Glucose (mg/dl) 97 ± 6 151 ± 8** 178 ± 15 246 ± 21* 131 ± 8 183 ± 10*
Chol (mg/dl) 133 ± 4 173 ± 10** 96 ± 8 147 ± 9** 105 ± 4 153 ± 4** 
TG (mg/dl) 63 ± 3 86 ±  4** 63 ± 3 87 ± 4*  79 ± 5 106 ± 8**
Insulin (ng/ml) not tested 0.80 ± 0.1 4.1 ± 0.7** 0.31 ± 0.07 1.84 ± 0.08***
HOMA (arbit U) not tested 57 ± 9 380 ± 80*** 18 ± 4 146 ± 28***
SGOT (IU/ml) 150 ± 19 165 ± 20 120 ± 23 249 ± 54 187 ± 13 173 ± 16
SGPT  (IU/ml) 158 ± 37 136 ± 16 74 ± 41 203 ± 67 129 ± 41 163 ± 45
AP (IU/ml) 122 ± 10 136 ± 18 192 ± 6 166 ± 19 124 ± 5 115 ± 6
1Initial weight 20.8 g at 8 weeks of age. 
2Initial weight 11.8 g at 4 weeks of age. 
values are mean ± sEm, *p < 0.05, **p < 0.01, ***p <0.001; male: 4 h post-fasting,   females: not fasted.
chol, cholesterol, Tg, triglycerides, sgOT, serum glutamic oxaloacetic transaminase, sgpT,  serum glutamic pyruvic 




T2DM: Both insulin and glucose more than 2.5 SD above 
control average.
Using these criteria, we have found in various experiments 
that close to 100% of PEG-SMLA-treated animals develop insu-
lin resistance in a time-dependent manner within 3 to 6 weeks 
of PEG-SMLA treatment and 30-60% exhibit symptoms of bor-
der-line T2DM.  In view of these results, we conclude that PEG-
SMLA treatment leads to the appearance of reversible metabolic 
syndrome and even T2DM phenotype.
In conclusion, administration of PEG-SMLA or even PEG-
MLA to mice causes reversible obesity, hyperglycemia and hy-
perinsulinemia. These findings raise questions as to whether 
islet β-cells are specifically affected by a LEPR blockade prevent-
ing their full compensation for insulin resistance. A second issue 
raised by these findings is the role of hepatic glucose production 
and insulin sensitivity in the rapid development of hyperglyce-
mia. Hypothalamic LEPRs have been implicated in the regula-
tion of hepatic glucose production, and direct effects of leptin on 
hepatocytes have also been demonstrated. The ability to rapidly 
and directly affect systemic and central nervous system (CNS) 
leptin signaling with high potency LEPR antagonists provides a 
powerful means of addressing the breadth of leptin action.
 As PEG-SMLA injection drastically changed several meta-
bolic parameters (Table 2), we decided to determine to what 
extent those metabolic changes affect or may be related to ex-
pression of several key genes in adipose tissue, muscle, liver and 
brain.  Over 40 different genes were tested and the results of all 
genes whose expression was significantly changed are present-
ed in Table 3. Supplemental Table S1 shows all the tested genes 
along with their full gene bank assignment. In adipose tissue a 
remarkable increase in leptin expression was already detected 
after one month and dramatically elevated after 3 months. It was 
paralleled by initial 5-fold decrease in expression of leptin recep-
tor that was normalized after 3 months. Similar but lesser de-
crease in leptin receptor was also observed in muscle.  In adipose 
tissue there was a gradual increase in expression of adiponectin, 
proinflammatory TNFα, and refeeding induced fat and liver fac-
tor and immediate and constant elevation of lipoprotein lipase 
which is also a ligand/bridging factor for receptor-mediated li-
poprotein uptake. It was paralleled by a decrease pyruvate dehy-
drogenase kinase (which down regulates production of AcCoA) 
all leading to increased fat synthesis.   Expression of  PPARγ that 
regulates fatty acid storage and glucose metabolism was elevated 
in PEG-SMLA treated mice. Genes activated by PPARγ stimu-
late lipid uptake and adipogenesis by fat cells. SCD1 which is 
an iron-containing enzyme that catalyzes a rate-limiting step in 
the synthesis of unsaturated fatty acids was also elevated in both 
adipose tissue and liver. It is known that SIRT1 is downregulated 
in cells that have high insulin resistance and inducing its expres-
sion increases insulin sensitivity, suggesting the molecule is as-
sociated with improving insulin sensitivity. We found such down 
regulation in both liver and muscle particularly after 3 months 
of PEG-SMLA treatment.  Liver expression of FGF21 stimulates 
glucose uptake in adipocytes was not changed after one month 
of PEG-SMLA treatment but after 3 months was drastically re-
duced possibly reflecting downregulation of SIRT1 known as its 
positive regulator.  Pyruvate kinase in the liver of PEG-SMLA 
treated mice was elevated indicating increased glycolysis.  This 
parallels to down regulation of PEPCK, the key enzyme upregu-
lating gluconeogenesis in both liver and muscle,  contrary to the 
situation usually occurring in T2DM where gluconeogenesis in 
elevated. It was suggested that UCP2-mediated mitochondrial 
uncoupling and reduced ROS formation in brain during sei-
zures could be neuroprotective (19). It seems that leptin block-
ing downregulated its brain expression at least after one month 
of treatment. Apolipoprotein E (apoE) that plays a central role 
in the brain response to injury was also downregulated after 
3-months PEG-SMLA treatment. Interestingly NPY a counter-
regulatory peptide of leptin in hypothalamus was elevated after 
one but not after 3 months of PEG-SMLA treatment.
Effect of leptin antagonists on bone metabolism and 
function
The putative role of leptin in bone metabolism was first dem-
onstrated in ob/ob (obese) or db/db (diabetic) mice which lack 
leptin or its receptor (20). Both mutant mice have an increased 
bone formation leading to high bone mass. This phenotype 
was dominant, independent of the presence of fat, and specific 
for the absence of leptin signaling. No leptin signaling in os-
teoblasts was observed but intracerebroventricular infusion of 
leptin caused bone loss in leptin-deficient and wild-type mice, 
thus identifying leptin as a potent inhibitor of bone formation 
acting through the CNS.  In sheep, central application of lep-
tin decreased bone formation by 70% and mineralizing surface 
(MS/BS, from 39.4 to 16.1 %, (p < 0.01), indicating that the cen-
tral regulation of bone formation is not limited to rodents, but 
is also found in large animals (21).  No similar results have been 
so far reported for humans. In contrast, in leptin deficient child 
the leptin-treated patient continued to gain height and accrue 
bone mass in keeping with predicted growth for age. Bone min-
eral content increased over the same period in keeping with age-
related growth. Bone age was advanced at time of diagnosis (8 
yr, 10 months at a chronological age of 5 yr), and remained ad-
vanced after 48 months of therapy (11 yr at a chronological age 
of 9 yr); however, the gap between bone age and chronological 
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table 3. gene expression at the end of the first and the third months in adipose, liver, muscle and brain tissues of control and 
pEg-smla-treated mice. The results were quantified by qpcR and normalized to gapDh mRna levels. Only the differences that 
were significantly changed either after one or three months or both are shown1.  
1The full list of all expressed genes and their bank numbers are listed in supplemental Table 1.
2genes in which no significant difference was found are not listed in this Table.
1st Month 3rd Month
Gene2 Control PEG–SMLA % p< Control PEG–SMLA % p<
Leptin 1.01 6.43 643 0.01 1.53 23.35 1526 0.01
LepR 1.10 0.23 20.9 0.05 1.09 0.94 86.2 ns 
Adiponec 1.01 1.10 110 ns 1.10 2.91 264.5 0.05
TNFα 1.25 1.17 93.6 ns 1.18 5.69 482.2 0.05
UCP2 1.04 2.42 232.6 0.05 1.05 1.21 115.2 ns 
LPL 1.05 2.29 218 0.05 1.14 3.78 331.5 0.05
SCD1 1.01 1.28 126.7 ns 1.15 2.62 227.8 0.05
PPARγ 1.01 4.85 480 0.05 1.11 2.17 195.4 0.05
PDK1 1.04 0.77 74 ns 1.23 0.51 41.4 0.05
RIFL 1.08 2.57 238 ns 1.21 2.76 228 0.05
1st Month 3rd Month
Gene2 Control PEG–SMLA % p< Control PEG–SMLA % p<
LR 1.06 0.88 83 ns 1.02 0.67 65.6 0.05
UCP3 1.12 3.48 310.7 0.05 1.05 1.09 103.8 ns 
PDK1 1.0 1.12 112 ns 1.01 0.68 67.3 0.05
GLUT1 1.04 1.08 103.8 ns 1.01 0.7 69.3 0.05
PEPCK 1.75 0.73 41.7 ns 1.27 0.23 18.1 0.05
SIRT1 1.02 0.93 91.1 ns 0.93 0.27 29 0.05
1st Month 3rd Month
Gene2 Control PEG–SMLA % p< Control PEG–SMLA % p<
UCP2 1.01 0.58 57.4 0.05 1.04 0.82 78.8 ns
apoE 1.00 1.01 101 ns 1.00 0.76 76 0.05
NPY 1.00 1.64 164 0.05 1.01 0.94 93 ns
SIRT1 1.02 1.35 132.3  ns 1.00 0.63 63 0.05
1st Month 3rd Month
Gene Control PEG–SMLA % p< Control PEG–SMLA % p<
SCD1 1.04 3.23 310.5 0.05 1.01 4.70 465.3 0.05
SIRT1 1.05 0.64 60.9 ns 1.00 0.78 78 0.05
PEPCK 1.04 0.50 48 0.05 1.02 0.80 78.4 ns 
PK 1.00 1.29 129 ns 1.01 1.65 163.3 0.05








Full name Short name Accession no.
leptin lep nm_008493
leptin receptor lR nm_146146
adiponectin adipo nm_009605
Tumor necrosis factor-alpha  TnFα nm_013693
Inhibitor of nuclear factor kappa-b kinase Ikkβ aF026524
uncoupling protein 2 ucp2 nm_011671
uncoupling protein 3 ucp3 nm_009464
caspase 3 casp3 nm_009810
bcl-2–associated X protein baX nm_007527
lipoprotein lipase lpl nm_008509
lipase lipe nm_010719
Fatty acid synthase Fasn nm_007988
sterol regulatory binding protein 1 sREbF1 nm_011480
sterol coenzyme a desaturase 1 scD1 nm_009127
silent information regulator 2 sirtuin protein sIRT1 nm_019812
peroxisome proliferator-activator receptor ppaRγ nm_001127330
Insulin dependent glucose transport 4 gluT4 nm_009204
glucose transport 1 gluT1 nm_01140
prohibitin phb nm_008831
protein disulfide isomerase associated 3 pDIa3 nm_007952
pyruvate dehydrogenase kinase pDk1 nm_172665
phosphofructokinase pFk nm_021514
Refeeding induced fat and liver RIFl nm_001080940
Transcription factor E2F1 E2F1 nm_007891
apoptosis signal-regulating kinase 1 ask1 nm_008580
apolipoprotein E apoE nm_009696
pro-opiomelanocortin  pOmc nm_008895
neuropeptide y npy nm_023456
Agouti related protein agRp nm_007427
silent information regulator (sirtuin) sIRT1 nm_019812
phosphoenolpyruvatecarboxy kinase pEpck nm_011044
glucose 6 phosphate g6pase nm_008061
peroxisome proliferator-activator receptor ppaRδ nm_011145
Insulin receptor IR nm_010568
aldolase a aldoa J05517
pyruvate kinase pk nm_013631
Fructose bisphosphatase 1 Fbp1 nm_019395
2,3-bisphosphoglycerate mutase bpgm nm_007563
phosphoglycerate kinase 1 pgk nm_008828
Fibroblast growth factor 21 FgF21 nm_020013
liver X receptor lXR nm_013839
pyruvate dehydrogenase phosphatase catalytic 
subunit 2
pdp2 nm_001024606
supplementary table 1. list of all genes tested for expression along with gene access number
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age had decreased significantly (22).  In contrast others (23, 24) 
observed that leptin-deficient mice had lower bone mass than 
normal mice. Studies in ob/ob mice have shown stimulatory ef-
fect of very high doses of intraperitoneal leptin administration 
on bone tissue, specifically, a dramatic increase in cortical bone 
formation (25).
As most of the experiments in mice were carried-out in genet-
ically modified animals we have decided the use the 3-months 
experiments shown above (Table 2) for testing the effect of 
blocking leptin on several bone parameters. LV3 and LV4 and 
tibias were removed after one and 3 months of treatment and 
analyzed for different bone criteria such as trabecular morpho-
metric analysis of LV3 and LV4, cortical morphometric analy-
sis of tibia and biomechanics 3-point bending test.  The results 
summarized in Table 4 indicated higher bone volume fraction 
(BV/BT) and increased trabecular thickness (Trb-Th) in LV3 
and LV4 of PEG-SMLA treated mice.  Visual demonstration of 
such difference is presented in Figure 2.  Cortical morphometric 
analysis of tibia showed increased cross-sectional and medul-
lary area and increase mean polar moment of inertia without 
changes in cortical thickness and BMD. Mechanical assay that 
measures the ultimate load required for fracture, the stiffness 
and the fracture yield showed significantly higher values in 
the PEG-SMLA treated mice.  Interestingly all the differences 
appeared already after one month of treatment of 4-weeks old 
mice. In addition a bone dynamic hystomorphometric analysis 
was performed by labeling bones on the day 20 of the experi-
ment by injecting Calcein, (15mg/kg) and by injecting Alizarin 
complexone (10 mg/kg) on day 26. Mean distance between la-
bels/time interval between labels (Fig. 3) indicated that the bone 
growth in mice injected with PEG-SMLA was (mean ± SEM, n 
= 5) 0.84 ± 0.05 versus control mice 0.63 ± 0.05 (p < 0.05). All 
those results favor the notion indicating that blocking leptin en-
hances bone formation. 
utilization of leptin antagonists for treatment of uremic 
cachexia 
Most recently, the negative role of leptin in uremic patients has 
table 4. Effect of long-term pEg-smla treatment on several bone structural and function parameters (for other details see Table 2). 
Parameter
tested
Control PEG-SMLA Control PEG-SMLA
after one month after three months
Trabecular morphometric analysis of LV3 and LV4
lv3-bv/Tv (%) 16.5±1.2 21.6± 0.8* 13.8±0.7  17.6±0.4*
lv3-Trb-Th (µ) 0.060±0.001 0.073±0.001* 0.061±0.001 0.072±0.001*
lv4-bv/Tv (%) 15.6±1.2 19.7± 0.7* 13.8±0.7  17.2±0.6*
lv4-Trb-Th (µ) 0.070±0.001 0.073±0.001 0.071±0.001 0.073±0.001
Cortical morphometric analysis of tibia
c.s.ar (µ2) 0.57±0.01 0.65±0.01* 0.72±0.03 0.84±0.03*
med-ar (µ2) 0.47±0.01 0.57±0.02* 0.48±0.03 0.57±0.03*
cor-Th (µ) 0.20±0.002 0.21±0.002 0.22±0.001 0.23±0.003
m-mlpolar (µ4) 0.15±0.005 0.22±0.01* 0.24±0.02 0.34±0.02*
bmD (g/cm3) 1.01±0.03 0.97±0.006 1.06±0.02 0.98±0.008
Biomechanics assay of tibia (3 point bending)
Fmax  (n) 19.2±0.4 21.1± 0.5* 24.3±0.7 27.6±0.8
stiffness (n/mm) 0.10±0.004 0.12±0.005* 0.10±0.01 0.16±0.01*
auc (n x mm) 8039±745 10513±758* 9903±0.03 11097±664*
Ffracture  (n) 14.7±0.7 15.3± 0.7 18.4±2.5 20.2±1.0
Fyield  (n) 14.6±0.4 16.2± 0.4* 16.5±0.7 21.6±0.6*
bv/Tv – bone volume/total volume; Trb-Th – trabecular thickness;  c.s.ar – cross-sectional thickness; c.s.ar – medullary area; 
cor-Th -  cortical thickness; m-mlpolar – mean polar moment of inertia; bmD – bone mineral density; Fmax – ultimate maximal 
load; auc – area under curve; Ffracture – Fracture load; Fyield – yield load.  n – neuton.
* significantly different compared to the respective control (p < 0.05).
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Figure 2. Typical micro-com-
puted tomographic 3D image 
of trabecular bone lumber 
vertebrae 3 (lv3) from the 
control (a) and pEg-smla (b) 
groups and respective  cross-
sectional image of trabecu-
lar bone lumber vertebrae 3 
(lv3) from the control (c) and 





Figure 3. bone Dynamic hys-
tomorphometric analysis of 
tibia growth was performed 
by labeling bones on the day 
20 of the experiment by inject-
ing calcein, (15mg/kg) and by 
injecting alizarin complexone 
(10mg/kg) on day 26. mean 
distance between labels/
time intervals between labels 
(maR) was measured.  ar-
rows indicate suitable sites of 
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table 5. pEg-smla treatment (28 days) in male mouse (c57bl/6J) model of cachexia in chronic kidney Disease (ckD) 1











n 8 8 12 12 12
Body parameters
Weight gain (%) 19.2±0.2b 42.7±0.3c 3.0±0.3a 3.7±0.3a 15.1±0.4b
Food intake (g/d) 3.9±0.2b 5.1±0.1c 3.1±0.2a 3.3±0.1a 3.9±0.1b
Fat mass change (%)2 8.0±4.2c 234.8±14e -8.3±0.8a -4.5±0.5b 24.5±3.0d
lean mass change (%)2 9.9±1.8d 14.8±1.6d -6.7±0.8a -3.7±0.4b 2.8±1.0c
bmR (ml/kg/h) x 10-3 3.4±0.08b 3.1±0.04a 3.9±0.06c 3.5±0.10b 3.2±0.08a
Muscle function parameters
Rotarod at 40 rpm (s)3 187±12b 153±13ab 130±3a 140±6a 176±4b
grip strength (g/100g)4 1646±61b 1697±28b 1150±49a 1321±52ab 1568±46b
paX 3 (expression)5 106±6c 98±6c 43±7a 44±6a 59±5b
atrogin-1 (expression)5 92±8a 111±5a 228±7d 178±9c 157±4c
muRF1 (expression)5 107±3a 125±4b 221±6e 177±8d      143±4c
Pro-inflammatory cytokines expression
Il-1α (expression)6 132±21a 156±24a 468±90d 345±38c 244±20b
Il-1β (expression)6 88±12a 97±18a 206±15c 140±19b 99±10a
Il-6 (expression)6 78±18a 115±28ab 438±55d 312±31c 187±20b
TnF-α (expression)6 99±25a 102±29a 192±17c 175±31bc 133±12ab
1ckD was induced by 5/6 nephrectomy in 8-week old male c57bl/6J mice. ckD and sham-operated mice received either 
pEg-smla (7 mg/kg or 2 mg/kg, i.p.) or vehicle, daily. mice were fed ad libitum for 28 days. all groups in the same row not 
designated with the same letter are significantly different (p < 0.05).
2Determined by DXa
3The rotarod performance test is a performance test based on a rotating rod with forced motor activity being applied, usually 
by a rodent. The test measures parameters such as riding time (seconds) or endurance.
4 grip strength test ia an easy way to objectively quantify the muscular strength of rodents (mouse and rat), and to assess the 
effect of drugs, toxins, muscular (i.e. myopathy) and neurodegenerative diseases on muscular degeneration.
5paX3 a member of the paired box (paX) family of transcription factors that was shown to contribute to early striated muscle 
developmenatrogin-1 is an E3 ubiquitin ligase that mediates proteolysis events in response to a variety of catabolic states in 
muscle; RIng-finger protein-1 (muRF1) is an ubiquitin ligase that has been proposed to trigger muscle protein degradation 
during pathophysiological muscle wasting. The expression was measured in muscle and normalized to expression of  gapDh 
(= 100).
6The expression was measured in liver and normalized to expression of gapDh (= 100). 
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been reviewed (26). Leptin has been defined as a true uremic 
toxin, and reducing leptin levels in uremic patients, particularly 
those suffering from uremia-related cachexia, may have poten-
tial beneficial effects. This suggestion is based on the finding 
that plasma leptin is associated with reduced energy intake and 
protein-wasting in uremic patients (27). In a murine model of 
uremic cachexia, application of pegylated superactive leptin an-
tagonist (Table 5) prevented lean and fat mass loss in chronic 
kidney disease (CKD) mice, reversed anorexia, normalized ba-
sal metabolic rate and muscle function. PEG-SMLA inhibited 
also protein degradation pathway genes and pro-inflammatory 
cytokines in CKD mice. Those results implicate that blocking 
leptin may be a suitable strategy for treatment of CKD patients.  
leptin antagonists as anticancer agents
The epidemiological evidence linking obesity and breast, cervi-
cal, colon, rectal, esophageal, gall bladder, kidney, liver, ovar-
ian, pancreatic, prostate, stomach and uterine cancers is well-
established (28-33); the high level of leptin in obese subjects 
thus raises the notion of a possible link between leptin and 
cancer. Leptin is an anti-apoptotic molecule in many cell types 
and its possible role in obesity-linked cancers originates from its 
known pro-angiogenic, pro-inflammatory and mitogenic activi-
ties. Furthermore, leptin was defined as a growth factor not only 
because of its proliferative activity but also due to its effect on 
cell motility and migration (34). Leptin is overexpressed in at 
least 80% of cases of human skin melanoma (35), breast (36), 
ovarian (37) and prostate (38) cancers. In most of those cases, 
LEPR is overexpressed as well (39). Interestingly, cancer stem 
cells, and particularly breast cancer stem cells, also overexpress 
LEPR, thus sensitizing those cells to leptin action (40). In one 
such cell type, termed triple-negative breast cancer cell, leptin 
attenuated the inhibitory effect of cisplatin on cell proliferation 
and viability (41). 
Leptin-induced modulation of colorectal cancer (CRC) has 
been reported in several in vitro and in vivo studies (reviewed 
in 48). Leptin’s stimulation of proliferation and inhibition of 
apoptosis have been shown in several human epithelial colon 
cancer cells, such as HT-29, CACO-2, DDL-1, SW480, HCT116, 
LS174-T and Lovo (42-44). However the in vivo role of leptin 
in CRC remains unclear. In spontaneous CRC models, such as 
in ApcMin/+ mice, leptin did not increase and even decreased 
intestinal tumorigenesis in ApcMin/+ mice, a mutation that 
predisposes the animal to tumor development in the intestine 
and colon (43, 45). In contrast, inflammation-induced CRC in-
duced by Dextrane Sodium Sulphate (DSS)-axoxymethane was 
attenuated in ob/ob and db/db mice as compared to wild-type 
mice (46).  Note that leptin’s effect may be indirect as leptin is 
known to induce inflammatory cytokines in colonic tissue that 
are implicated in colon carcinogenesis, such as IL6, IL1β and 
CXC (47). Likewise the impact of leptin on colon cancer in hu-
mans remains unclear. While some reports show increased lep-
tin expression with progressing tumorigenesis, other have failed 
to confirm such observations (48). However, it should be noted 
that serum leptin levels may not be indicative of local leptin lev-
els. Putatively, blocking localized leptin secretion by leptin an-
tagonists endocscopically applied to colon cancer cells may be 
considered as a possible future treatment option.
The role of leptin in hepatocellular carcinoma (HCC), the 
third leading cause of cancer death in the world, is also not 
clear. Patients with cirrhosis resulting from hepatitis B or C 
infection were found to exhibit increased leptin levels which 
were suggested to represent a negative prognostic factor (49), 
but again, studies have reported contradictory findings (50). 
Another major factor leading to HCC is non-alcoholic fatty liv-
er disease (NAFLD) ranging from simple steatosis to non-alco-
holic steatohepatitis (NASH). In an animal model of NAFLD, 
leptin was suggested to contribute to insulin resistance and 
steatosis, and leptin injections increased the expression of pr-
ocollagen-I, TGF-β1 and smooth muscle actin (all markers for 
HCC), and led to increased liver fibrosis (51). In another study 
without leptin signaling, neither fibrosis nor HCC developed 
in the rat NASH model (52). However, contradictory to other 
reports exogenous leptin significantly decreased tumor size 
and increased survival rate in an HCC mouse model (53). In 
human studies, leptin levels were significantly higher in NASH 
patients and correlated with severity of hepatic steatosis (54), 
but in another study no differences were found (55). Further-
more, high leptin expression correlated with better survival in 
HCC patients (56).   
More recently, attention has been given to the role of leptin in 
glioblastoma and is reviewed elsewhere (34). Though extensive 
in vivo studies are still lacking and the information linking leptin 
to glioblastoma stems mainly from studies with glioma cell line 
C6 (57,58), the authors strongly suggest leptin’s role not only in 
cell proliferation and inhibition of apoptosis but also in leptin-
enhaced cell migration (59). Moreover, indirect leptin actions 
such as promotion of angiogenesis and augmentation of VEGF 
levels may also play an important role in leptin promotion of 
glioblastoma and other cancers (60-63).    
One of the most interesting findings connecting leptin to 
susceptibility to cancer in mouse models of melanoma and co-
lon cancer, related to environmental enrichment, showed that 
mice kept in an enriched environment express higher levels of 
brain-derived neurotrophic  factor (BDNF), which in turn ac-
tivates sympathetic nerve fiber innervation of white adipose 
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tissue, resulting in decreased leptin secretion, cancer inhibition 
and remission (64). Thus, although the role of leptin in tumor 
promotion is controversial and may depend on tumor type, at 
least in those cases in which leptin plays a negative role, leptin 
antagonists may be potentially used as both important research 
tools and potential therapeutic modalities. 
leptin antagonists as potential anti-inflammatory and 
anti-autoimmune disease treatments
For years, white adipose tissue has been regarded as an inert 
organ, with the exclusive function of long-term energy stor-
age. With the cloning of leptin in 1994, that notion has changed 
drastically (1). In subsequent years, a plethora of tissue-specific 
and nonspecific adipose-secreted factors were discovered and 
characterized and found to play fundamental roles in multiple 
aspects of cardiometabolic processes. Moreover, white adipose 
tissue has been found to dynamically integrate metabolic and 
immune signals through interactions between adipocytes and a 
complex network of innate and adaptive immune cells, including 
neutrophils, mast cells, and mononuclear T and B cell subsets. 
Through this complex interaction it was suggested that immune 
components fundamentally affect metabolic processes such as 
insulin sensitivity, and conversely, adipocyte-secreted factors af-
fect the innate and adaptive immune response through modula-
tion of tissue-resident cells of hematopoietic origin (65, 66). 
Leptin, the prototypical adipokine, has been most widely 
studied for its effects on the immune response.  Leptin secretion 
is inducible upon signaling from inflammatory mediators such 
as tumor necrosis factor-alpha (TNF-α), IL1, and IL6. Indeed 
leptin levels have been suggested to increase during infection 
and chronic inflammation (67). Like leptin itself, LEPRs resem-
ble cytokine receptors (68) and the long functional isoform of 
LEPR is found on T-cell subsets, monocytes (69), natural-killer 
(NK) lymphocytes (70), dendritic cells (71), hepatic stellate cells 
(72) and a variety of bone marrow progenitor cells. Functionally, 
leptin signaling promotes macrophage proliferation, phagocy-
tosis and cytokine secretion (73), NK cell development, activa-
tion and survival (74), MAPK-mediated neutrophil chemotaxis 
(75), T-cell proliferation and IL2 secretion, especially when co-
administered with classical T-cell mitogens (76). Leptin has also 
been suggested to suppress regulatory T-cell proliferation and 
inflammation suppressive functions, further contributing to a 
general pro-inflammatory effect (77). 
In vivo, leptin-deficient ob/ob mice are extremely vulnerable 
to the development of systemic infection and lipopolysaccha-
ride (LPS)-induced organ damage, and resistant to several Th1 
cells-mediated immune disorders, including experimental aller-
gic encephalomyelitis, concanavalin A hepatitis, experimental 
arthritis, and autoimmune nephritis (78-80). Leptin replenish-
ment reverses these disorders (81). These mice feature reduced 
cell density in their bone marrow and thymus, highlighting the 
importance of leptin signaling in the development of various 
subsets of the hematopoietic system. Similarly, humans with in-
herited or starvation-induced leptin deficiency feature thymic 
atrophy and severe functional alterations in the innate and adap-
tive immune response, rendering them susceptible to bacterial 
infection (82, 83). 
In humans, the causative correlation between leptin levels 
and the propensity and severity of autoimmune disease remains 
controversial. Perhaps the strongest association between leptin 
levels and autoimmunity has been found in multiple sclerosis 
(MS), a T-cell-mediated autoimmune disorder of the CNS; ob/
ob mice are protected from EAE, the most common small ani-
mal model of MS, possibly through leptin-deficiency-induced 
expansion of nTregs cells  (84,85). In humans, leptin levels have 
been suggested to correlate with disease activity and to decrease 
following successful treatment with interferon beta (INF-β) 
(86). In other systemic autoimmune disorders, such as rheu-
matoid arthritis and systemic lupus erythematosus, leptin levels 
have been suggested in some, but not all, reports to be elevated 
independently of gender or weight and to possibly correlate 
with disease severity (87-92). Interestingly, one study suggested 
that acute fasting promotes improvement in multiple immune 
parameters in rheumatoid arthritis patients, an effect that may 
be linked to the reduced leptin levels in these patients (93). 
Similarly, leptin was suggested to contribute to the pathogen-
esis of diabetes mellitus in mice, while a mutation in the LEPR 
of mice with a NOD background ameliorated diabetes severity 
in these mice (94,95). Yet another example of leptin’s effect on 
the immune response was recently demonstrated by our groups 
(96), whereby administration of competitive leptin antagonists 
induced significant amelioration in a model of chronic liver in-
flammation and fibrosis. 
A role for leptin was suggested in the pathogenesis of intes-
tinal autoinflammation. Inflammatory bowel disease (IBD) is 
a chronic inflammatory disorder affecting 0.3% of the West-
ern population; its pathogenesis is thought to result from loss 
of tolerance of the intestinal immune system in the presence of 
constant antigenic stimuli mediated by resident microflora. In 
recent years, mounting evidence has suggested that IBD patho-
genesis is closely related to a combination of abnormal challeng-
es by normal gut microflora, coupled with inherent or acquired 
aberrations in the intestinal innate immune response. Leptin’s 
central role as a mediator of colonic autoinflammation has been 
suggested in both animal models and human studies. Leptin-
deficient ob/ob mice are resistant to acute and chronic experi-
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mental colitis (97,98). In those studies, leptin was suggested to 
augment pro-inflammatory cytokine secretion, including IFN-
g, TNF-α, IL-18, IL-1β, and IL-6, and to inhibit inflammation-
associated apoptosis of colonic mononuclear cells. Inflamed co-
lonic epithelial cells were also found to express and release leptin 
apically into the intestinal lumen. Intrarectal administration of 
leptin induced activation of NF-κB and epithelial wall damage 
associated with neutrophil infiltration (99).  The source of local 
and/or systemic leptin has not been elucidated, but it has been 
suggested not to be lamina propria T cells themselves. Similarly, 
the leptin-responsive cells have not yet been identified. Collater-
al evidence for a possible pro-inflammatory interaction between 
leptin and lamina propria dendritic cells (lpDCs) comes from 
studies showing that LEPRb is expressed on immature and ma-
ture human DCs, and that leptin induces STAT3 and NF-κB ac-
tivation, production of IL-1, IL-6, IL-12, TNF-α and MIP-1α, an 
anti-apoptotic effect through Bcl-2 and Bcl-XL, downregulation 
of IL-10, polarization into Th-1, and increased CD40 expression 
(100,101). In human IBD patients, leptin levels have been sug-
gested to correlate with the severity of the disease (102-104). 
Taken together, a large body of evidence suggests an asso-
ciation between leptin levels and responsiveness in terms of 
propensity for autoimmunity, autoinflammation and infec-
tion. While much of the current data, particularly in humans, 
is observational and associative, they suggest that leptin may 
play direct or indirect roles in the modulation and regulation 
of innate and adoptive immune responses and that excessive 
leptin signaling might result in a deleterious tendency toward 
autoinflammation in susceptible populations. As such, inhibi-
tion of leptin signaling, as we have recently suggested, may offer 
a unique therapeutic modality targeting leptin signaling in the 
autoinflammatory setup. 
leptin antagonists in other pathologies 
The role of leptin signaling in myocardial hypertrophy, heart 
diseases associated with metabolic syndrome, endothelial dys-
function, arterial hypertension, and neurodegenerative diseases 
(e.g., Alzheimer’s and Parkinson’s) are beyond the scope of the 
present review. However, in all these conditions, leptin’s negative 
effects can be potentially antagonized by leptin antagonists.
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